Table 3.

Mutations in BCR pathway members in pretreatment archival tumor tissue or CSF

Patient IDDiseaseCOO/statusBest response (duration, mo)MYD88CD79BCARD11MALT1TNFAIP3PLCG2
#5 PCNSL ABC/recu CR (24)* L265P (C) Y196H (C) WT (C) WT (C) WT (C) WT (C) 
#8 PCNSL ABC/recu CR (19.4)* L265P (C) Y196H (C) WT (C) WT (C) WT (C) WT (C) 
#12 PCNSL ABC/recu CR (16.7)* WT (C) Y196H (T) WT (C) WT (C) WT (C) WT (C) 
#4 PCNSL ABC/recu CR (9.2) L265P (T) X185splice/D185N (T) F97Y (T) WT (T) WT (T) WT (T) 
#9 PCNSL ABC/recu CR (4.3) WT (C) WT (C) WT (C) WT (C) WT (C) WT (C) 
#7 PCNSL ABC/recu CR (4) WT (C) WT (C) M166T (C) WT (C) WT (C) WT (C) 
#13 PCNSL ABC/recu PR (4.3) L265P (T) Y196S (T) R418K (T) WT (T) WT (T) WT (T) 
#15 PCNSL GCB/recu PR (3.8) L265P (C) Y196S/D201G (C) WT (C) WT (C) WT (C) WT (C) 
#10 PCNSL GCB/refr PD (0.9) WT (T) WT (T) T128M/K252E (T) WT (T) WT (T) WT (T) 
#14 SCNSL GCB/new CR (13.8)* L265P (C) Y196C (C) WT (C) WT (C) WT (C) WT (C) 
#6 SCNSL ABC/new PR (4.47) L265P (T) WT (T) WT (T) AMP (T) WT (T) WT (T) 
#1 SCNSL GCB/recu PR (4) D288_F298del (T) Y196F/M164I (T) K215M (T) WT (T) C483W (T) WT (T) 
#11 SCNSL GCB/new PR (3.4) A272P (C) WT (C) S66A/L251P/R418S (C) WT (C) WT (C) WT (C) 
#2 SCNSL GCB/refr SD (1.5) WT (T) WT (T) WT (T) WT (T) WT (T) R268W (T) 
#3 SCNSL GCB/refr PD (0.9) WT (C) WT (C) WT (C) WT (C) WT (C) WT (C) 
Patient IDDiseaseCOO/statusBest response (duration, mo)MYD88CD79BCARD11MALT1TNFAIP3PLCG2
#5 PCNSL ABC/recu CR (24)* L265P (C) Y196H (C) WT (C) WT (C) WT (C) WT (C) 
#8 PCNSL ABC/recu CR (19.4)* L265P (C) Y196H (C) WT (C) WT (C) WT (C) WT (C) 
#12 PCNSL ABC/recu CR (16.7)* WT (C) Y196H (T) WT (C) WT (C) WT (C) WT (C) 
#4 PCNSL ABC/recu CR (9.2) L265P (T) X185splice/D185N (T) F97Y (T) WT (T) WT (T) WT (T) 
#9 PCNSL ABC/recu CR (4.3) WT (C) WT (C) WT (C) WT (C) WT (C) WT (C) 
#7 PCNSL ABC/recu CR (4) WT (C) WT (C) M166T (C) WT (C) WT (C) WT (C) 
#13 PCNSL ABC/recu PR (4.3) L265P (T) Y196S (T) R418K (T) WT (T) WT (T) WT (T) 
#15 PCNSL GCB/recu PR (3.8) L265P (C) Y196S/D201G (C) WT (C) WT (C) WT (C) WT (C) 
#10 PCNSL GCB/refr PD (0.9) WT (T) WT (T) T128M/K252E (T) WT (T) WT (T) WT (T) 
#14 SCNSL GCB/new CR (13.8)* L265P (C) Y196C (C) WT (C) WT (C) WT (C) WT (C) 
#6 SCNSL ABC/new PR (4.47) L265P (T) WT (T) WT (T) AMP (T) WT (T) WT (T) 
#1 SCNSL GCB/recu PR (4) D288_F298del (T) Y196F/M164I (T) K215M (T) WT (T) C483W (T) WT (T) 
#11 SCNSL GCB/new PR (3.4) A272P (C) WT (C) S66A/L251P/R418S (C) WT (C) WT (C) WT (C) 
#2 SCNSL GCB/refr SD (1.5) WT (T) WT (T) WT (T) WT (T) WT (T) R268W (T) 
#3 SCNSL GCB/refr PD (0.9) WT (C) WT (C) WT (C) WT (C) WT (C) WT (C) 

Mutations are highlighted in bold.

(C), CSF; COO; cell of origin; recu, recurrent tumor; refr, refractory tumor; (T), archival formalin-fixed paraffin-embedded tissue; WT, wild-type.

*

Ongoing treatment with study drug.

Treated with high-dose chemotherapy with autologous stem cell rescue.

Close Modal

or Create an Account

Close Modal
Close Modal